Panacur Equine Guard 10% w/v Oral Suspension

País: Reino Unido

Língua: inglês

Origem: VMD (Veterinary Medicines Directorate)

Ingredientes ativos:

Fenbendazole

Disponível em:

MSD Animal Health UK Limited

Código ATC:

QP52AC13

DCI (Denominação Comum Internacional):

Fenbendazole

Forma farmacêutica:

Oral suspension

Tipo de prescrição:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Grupo terapêutico:

Horses

Área terapêutica:

Anthelmintic

Status de autorização:

Authorized

Data de autorização:

2000-09-05

Características técnicas

Revised: December 2020
A/N: 01394/2020
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Guard 10% w/v Oral Suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance(s):
% w/v
Fenbendazole
10.000
Excipients
Sodium Methyl Parahydroxybenzoate
0.200
Sodium Propyl Parahydroxybenzoate
0.0216
Benzyl Alcohol
0.4835
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral suspension.
A white, aqueous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and other equines
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult and immature roundworms of the
gastro-intestinal tract in horses and other equines.
The product is also effective for the treatment and control of
encysted mucosal
3rd and 4th stage small strongyle larvae and is also effective against
encysted
inhibited 3rd stage small strogyle larvae in the mucosa.
The
product
is
also
effective
in
controlling
other
immature
and
mature
roundworms including large redworm (_Strongylus edentatus _ and _
Strongylus _
_vulgaris_)
and
migrating
large
redworm,
_Ascarids _
(_Parascaris _
_equorum_),
_Oxyuris_ and _ Strongyloides_ species and benzimidazole susceptible
adult and
immature small strongyles (Cyathostomes).
The product also has an ovicidal effect on nematode eggs.
Revised: December 2020
A/N: 01394/2020
Page 2 of 5
4.3
CONTRA-INDICATIONS
None known.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Under dosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing
device (if any).
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal